Invention Grant
US09539264B2 Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
有权
使用2-亚甲基-19-去甲 - （20S）-1-α，25-二羟基维生素D 3治疗先前用仿效物治疗的患者继发性甲状旁腺功能亢进
- Patent Title: Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
- Patent Title (中): 使用2-亚甲基-19-去甲 - （20S）-1-α，25-二羟基维生素D 3治疗先前用仿效物治疗的患者继发性甲状旁腺功能亢进
-
Application No.: US14710746Application Date: 2015-05-13
-
Publication No.: US09539264B2Publication Date: 2017-01-10
- Inventor: Hector F. DeLuca , Lori A. Plum , Margaret Clagett-Dame
- Applicant: Wisconsin Alumni Research Foundation
- Applicant Address: US WI Madison
- Assignee: Wisconsin Alumni Research Foundation
- Current Assignee: Wisconsin Alumni Research Foundation
- Current Assignee Address: US WI Madison
- Agency: Andrus Intellectual Property Law, LLP
- Main IPC: A61K31/59
- IPC: A61K31/59 ; A61K31/593 ; A61K45/06
Abstract:
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
Public/Granted literature
Information query
